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Abstract
Background: The word selectivity describes a drug's ability to affect a particular cell population
in preference to others. As part of the current state of art in the search for new therapeutic agents,
the property of selectivity is a mode of action thought to have a high degree of desirability.
Consequently there is a growing activity in this area of research.
Selectivity is generally a worthy property in a drug because a drug having high selectivity may have
a dramatic effect when there is a single agent that can be targeted against the appropriate
molecular-driver involved in the pathogenesis of a disease. An example is chronic myeloid leukemia
(CML). CML has a specific chromosomal abnormality, the Philadelphia chromosome, that results in
a single gene that produces an abnormal protein
Discussion: There is a burgeoning understanding of the cellular mechanisms that control the
etiology and pathogeneses of diseases. This understanding both enables and motivates the
development of drugs that induce a specific action in a selected cell population; i.e., a targeted
treatment. Consequently, drugs that can target distinct molecular targets involved in pathologic/
pathogenetic processes, or signal-transduction pathways, are being developed.
However, in most cases, diseases involve multiple abnormalities. A disease may be associated with
more than one dysfunctional protein and these may be out-of-balance with each other. Likewise a
drug might strongly target a protein that shares a similar active domain with other proteins. A drug
may also target pleiotropic cytokines, or other proteins that have multi-physiological functions. In
this way multiple normal cellular pathways can be simultaneously influenced. Long term experience
with drugs supposedly designed for only a single target, but which unavoidably involve other
functional effects, is uncovering the fact that molecular targeting is not medically flawless.
Summary: We contend that an ideal drug may be one whose efficacy is based not on the inhibition
of a single target, but rather on the rebalancing of the several proteins or events, that contribute
to the etiology, pathogeneses, and progression of diseases, i.e., in effect a promiscuous drug. Ideally,
if this could be done at minimum drug concentration, side effects could be minimized. Corollaries
to this argument are that the growing fervor for researching truly selective drugs may be imprudent
when considering the totality of responses; and that the expensive screening techniques used to
discover these, may be both medically and financially inefficient.
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Background
The words selectivity, specificity, and sensitivity (derived
from Latin seligere, specificus, sensitivus), can be confus-
ing terms as they are often used synonymously in the
medical literature. However, they should not be used
interchangeably as each represents a different phenome-
non. For the sake of consistency and clarity, this paper will
use the terms as defined below:
Selectivity will be used to describe the ability of a drug to
affect a particular population, i.e., gene, protein, signaling
pathway, or cell, in preference to others. For example a
selective drug would have the ability to discriminate
between, and so affect only one cell population, and
thereby produce an event.
Specificity, a term most often confused with selectivity,
will be used to describe the capacity of a drug to cause a
particular action in a population. For example, a drug of
absolute specificity of action might decrease or increase, a
specific function of a given gene or protein or cell type, but
it must do either, not both.
Sensitivity will be used to describe the capacity of a popu-
lation, to respond to a drug's ability, to stimulate that
entity at a specified dose. The smaller the dose required
producing an effect, the more sensitive is the responding
system. (The word used to describe this activity in the drug
which is the cause of the population sensitivity, is
potency).
It can be seen therefore, that a drug's activity may involve
all the above attributes-it may be selective to one cell pop-
ulation, and also be specific to one kind of action on that
cell population, and the population in turn, may be sen-
sitive to the drug's influence at a lower dose than would
other responding systems.
As part of the current state of art in the search for new ther-
apeutic agents, the property of selectivity is a mode of
action thought to have a high degree of desirability and
there is a great deal of activity in this area of research. It is
the growing understanding of the cellular mechanisms
that control etiology of diseases together with modern
technology that enables and motivates the development
of targeted therapies. This search for selective drugs has
led to the development of high-throughput, virtual
screening, and rational drug design techniques that are
widely used to discover leads for drug candidates. Suc-
cesses have lead to small molecular drugs that can target
specific proteins involved in signal-transduction pathways
leading to pathogenesis. Indeed, a drug having high selec-
tivity may have a dramatic effect when there is a single
agent that can be targeted against the appropriate molec-
ular-driver involved in the pathogenesis of a disease. An
example is chronic myeloid leukemia that has a specific
chromosomal abnormality called the Philadelphia chro-
mosome that results in a gene that produces an abnormal
protein. However a protein being targeted may share a
similar active domain with other proteins having normal
physiologic functions; hence this would cause undesira-
ble side effects. Long term experience with drugs suppos-
edly designed for only a single target, but which
unavoidably involve other functional effects, is uncover-
ing the fact that molecular targeting is not medically flaw-
less. The recent discovery related to Cox -2 inhibition is
the most striking example [2].
Discussion
Selectivity is generally a worthy property in a drug, e.g., it
is desirable to have a chemotherapy drug to affect prostate
cancer cells and not affect nearby healthy prostate cells
and other normal tissues. Similarly an anti-bacterial for
germs or parasites should be suitably potent so that it can
be used in a small dose sufficient to kill the infectious
agents but not to affect host cells. Sometimes, however,
selectivity is undesirable as in a case where a drug strongly
targets pleiotropic cytokines or other proteins that have
multifunctional effects and so can influence multiple cel-
lular pathways simultaneously. Important examples are
TNF-α  and cyclic AMP, both of which have a variety of
effects in a cell, pathogenetically and physiologically.
TNF-α  has a dual nature in cell death and cAMP acts to
control a protein kinase that in turn affects activities of a
variety of cellular proteins [3-5].
The strategy for selective drug development is based on
the abundant progress made in the last decade in human
genomic and proteomic projects. For example, a major
related effort is structure-based drug design. Here the
three-dimensional structure of a drug target interacting
with small molecules is used to guide drug discovery.
Structure-based design enables a researcher to "see"
exactly how a molecule interacts with its target protein
and so bind a selective agent to the target.
Specifically, cancer treatment is rapidly evolving from sys-
temic, non-specific, high-dose chemotherapy to a wide
variety of targeted therapies. Advances in molecular genet-
ics, and immunology, along with improved laboratory
techniques, have led to the discovery of unique targets
integral to the growth and proliferation of malignant cells.
These revolutionary discoveries provide a foundation for
the development of a new generation of anti-tumor
agents. They include such new targeted, non-cytotoxic
anticancer agents, as small-protein kinase inhibitors.
Examples are the FDA approved tyrosine kinase inhibi-
tors, Gleevec [Gleevec (imatinib mesylate); Novartis Phar-
maceuticals Corp.], Iressa (gefitinib); Astra ZenecaBMC Clinical Pharmacology 2005, 5:3 http://www.biomedcentral.com/1472-6904/5/3
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Pharmaceuticals Inc.], and others that are in various stages
of clinical development. [6]
Another example, with a different targeting mechanism, is
the humanized monoclonal antibody bevacizumab
(Avastin; Genentech). This agent targets and inhibits the
function of the vascular endothelial growth factor (VEGF)
that stimulates new blood vessel formation; and is there-
fore an anti-angiogenesis agent. It is currently approved as
a first-line treatment for patients with metastatic colorec-
tal cancer [7].
In addition to treatment of cancer there are new targeting
agents known as biological response modifiers (BRMs).
These target specific cytokines such as TNF-α  and IL-1.
These are being used for the treatment of diseases having
an inflammatory component such as inflammatory bowel
disease (IBD) and rheumatoid arthritis (RA). In the case of
IBD they are the drugs of choice and for RA they are prov-
ing to be more effective than traditional disease-modify-
ing antirheumatic drugs (DMARDs), especially when used
in combination treatment such as with methotrexate.
Four targeted drug therapies are approved for use in IBD
and/or RA; three target TNF-α  (1) etanercept; Enbrel,
Amgen Inc. (A TNF-α  decoy receptor). (2) infliximab;
Remicade, Centocor Inc. and (3) adalimumab; Humira,
Abbott Laboratories Inc. (both TNF-α  monoclonal anti-
bodies) and one that targets IL-1 (4) anakinra; Kineret,
Amgen Inc. A reason why this problem is arising for the
above three strong TNF-α  inhibitors may be because TNF-
α  has a dual nature. It triggers the JNK-dependent pathway
required for TNF-α -induced apoptosis and it also activates
the protein. PI3-kinase, associated with cell survival that
can block this very pathway. This dual nature thus sets up
a "delicate life-death balance" in the cell. This finding
originally brought with it increased hope for the use of
TNF-α  as a possible treatment against cancer. [8-10].
Strategies for targeting a single genes or proteins ignore a
very important fact that the most, if not all of diseases
involve a sophisticated network "system" [11]. For exam-
ple, chemokines, a family of immune molecules related to
IL-8 contains approximately 50 ligands and 20 receptors,
often acting with redundancy, thus making selection of
appropriate specific antagonists not only difficult, but
lacking in long-term efficacy [12]. This argument is sup-
ported by the fact that many agents recently developed by
targeting a specific molecule for the treatment of IBD are
proving to be either insufficiently effective or totally inef-
fective. The examples of insufficient efficacy include p55-
TNF binding protein, interferon α , β -a, interferon γ  anti-
body, IL-12 antibody, P65 antisense oligo, G-CSF, GM-
CSF, EGF, hGH, keratinocyte GF-2, CD4 antibody and
α 4β 7-intergrin antibody whereas ineffectiveness includes
IL-10, IL-11, ICAM-1 antisense, TNFR2 fusion protein
Enbrel.
Many of single-targeted drugs mentioned above have
been clinically proven effective in short term. For exam-
ple, the treatment with biologic DMARDs relieves symp-
toms, inhibits the progression of structural damage, and
improves physical function in patients with moderate to
severe active RA. The 3 marketed TNF-α  blocking agents
have similar efficacy when combined with MTX, a widely
used DMARD, in the treatment of patients with RA [13].
While providing significant efficacy and a good overall
safety profile in the short and medium term in many
patients with RA, these biologic treatments, however, may
create serious problems and long-term side effects, such as
on the liver, and still need to be evaluated. There has been
a disturbing association between the use of both of Enbrel
or Remicade and the development of lymphoma [14]. As
described above, several reports have shown that patients
treated with Enbrel or Remicade worsen their congestive
heart failure and develop serious infection and sepsis, and
increase exacerbations of multiple sclerosis and other cen-
tral nervous system problems [15,16]. It is because many
pathogenetic targets also have their multiple physiologi-
cal functions and so can influence multiple cellular path-
ways simultaneously.
Nevertheless short-term side effects of all of the above
drug treatments have been thought to be generally man-
ageable. However, as they are relatively new agents,
extended follow-ups are revealing unanticipated longer
term results. As one example, imatinib, the first major
drug in its class of specific inhibitors of tyrosine kinase
receptors, has been found to be far less effective in
patients who relapsed with accelerated and blast phases of
CML [1]. It is therefore being recommended for use either
as an alternative, or as an adjunct to donor lymphocyte
infusions for patients with stable phase myeloid leukemia
who relapse after allogeneic stem cell transplantation. It is
not surprising that after a particular protein is targeted,
resistance to a drug can evolve when cancer cells create a
by-pass to the targeted activity. As a result, the emergence
of resistance to imatinib has been recognized as a major
problem in the treatment of CML. Therefore, regimens
that combine imatinib with conventional chemothera-
peutic agents, or with inhibitors of other signal transduc-
tion proteins that may be preferentially activated in CML
cells are being pursued [17,18].
Two other very recent examples (2005) of drugs having a
high degree of selectivity but nevertheless failed to live up
to expectations or had unanticipated adverse events, are
Iressa, a specific epidermal growth factor inhibitor which
has a variety of side effects originally thought to be accept-
able in light of its anti-cancer activity. However, IressaBMC Clinical Pharmacology 2005, 5:3 http://www.biomedcentral.com/1472-6904/5/3
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failed to significantly prolong survival in comparison to
placebo or in patients with adenocarcinoma [19]. The
other, Tysabri, is a laboratory-produced monoclonal anti-
body which is the first of a new class of agents known as
selective adhesion molecule (SAM) inhibitors. Tysabri
was pulled from the market, and clinical trials of Crohn's
diseases and rheumatoid arthritis were suspended because
of two cases of progressive multifocal leukoencephalopa-
thy (PML) [20].
An interesting and to the point of this paper, is the publi-
cation by Roth et al., in "Nature Reviews". The authors dis-
cuss the concept of using selective versus non-selective
drugs for central nervous system (CNS) disorders. Since in
most cases, multiple molecular lesions or signaling path-
ways are involved in pathogenesis of CNS disorders, the
authors conclude that attempts to develop more effective
treatments for diseases such as schizophrenia and depres-
sion by discovering drugs selective for single molecular
target that is, "magic bullets" have, not surprisingly, been
largely unsuccessful. They propose that "designing selec-
tively non-selective drugs (that is, 'magic shotguns') that
interact with several molecular targets will lead to new
and more effective medications for a variety of central
nervous system disorders" [21].
At the 10th anniversary conference of The Society for Bio-
molecular Screening a presentation on single vs. combina-
tion drugs concluded that "During the last decade, the
industry has followed an assumption that a single drug
hitting a single target was the 'rational' way to design
drugs. Now post-genomics biology is teaching us the fun-
damental limitations of the single target philosophy. Iron-
ically many drugs on the market, discovered in 'black box'
phenotype screens, are observed to bind potently to mul-
tiple targets and more so, this poly-pharmacology is key to
their effect (personal communication; Andrew Hopkins,
Pfizer Global Research & Development -United Kingdom;
The Society for Biomolecular Screening, 10th anniversary
conference, September 14, 2004, Point/ Counterpoint –
Polypharmacology: Single vs. Combination Drug)
A case in point is found in another recent study that com-
bined an anti-EGFR monoclonal antibody and tyrosine
kinase inhibitor, which target extra-cellular and intracellu-
lar domains of the receptor, respectively. Specifically, the
combination of cetuximab (Erbitux, ImClone Systems,
with either gefitinib (Iressa, AstraZeneca, or erlotinib
(Tarceva, Genentech) across a variety of human cancer
cells. The combination of cetuximab plus gefitinib or erlo-
tinib enhanced growth inhibition over that observed with
either agent alone. The study concludes that "together,
these data suggest that combined treatment with distinct
EGFR inhibitory agents can augment the potency of EGFR
signaling inhibition. This approach suggests potential
new strategies to maximize effective target inhibition,
which may improve the therapeutic ratio for anti-EGFR-
targeted therapies in developing clinical trials" [22].
At the American Society of Clinical Oncology annual
meeting held in June, 2004, scientists discussed the con-
cept of drug promiscuity. The focus here was in some
cases, a drug that attacks multiple but limited targets may
keep cancer cells from developing resistance [23].
The examination of the role of deregulated cell cycle pro-
gression and uncontrolled cellular proliferation can also
elucidate the advisability of hitting multiple targets simul-
taneously in order to show superior efficacy. Uncon-
trolled proliferation is a condition found in a variety of
diseased cells. It is a feature of cellular transformation,
accompanied by the deregulation of Cyclin dependent
Kinases (Cdks) involved in the control of the cell cycle,
check points, and apoptosis which has a crucial role in the
growth of both normal and malignant cells [24,25].
Apoptosis is an energy-dependent, normal process of cell
death, based on morphological and biochemical changes
in the cell that occurs in many biological conditions, but
without concurrent pathological necrosis and inflamma-
tion [26].
Since immune cells in bone marrow (B-cells) or in the
thymus (T-cells) undergo repeated cycling as part of their
development, cell proliferation is a fundamental process-
within the immune system function [27-29]. Immune
based diseases with a component of inflammation are risk
factors for the development of several diseases including
cancer, and it is known that anti-inflammatory agents
markedly inhibit the development of cancer in humans;
e.g., colon cancer [30]. Although the specific intracellular
pathways and networks involved in these processes are
not completely understood, at the molecular level, this is
thought to be based on the combination of cellular trans-
formation and cellular proliferation. The normal cell cycle
and its intricate mechanism when deregulated (by germ
or somatic factors) can lead to uncontrolled cellular pro-
liferation, defective apoptosis, autoimmunity and inflam-
mation and uncontrolled proliferation and defective
apoptosis, can be viewed as both cause and consequence
ofinflammation, cancer, and autoimmunity [31-34].
Multiple target drug screening approaches are being devel-
oped. As indicated, the pathogenesis of a disease is usually
multi-factorial involving numerous risk factors and defec-
tive genes or proteins or signaling pathways out of balance
with each other. There may be one major or most easily
definable defective target (or pathway)externalized or typ-
ifiedfor a given disease, but collateral proteins which can
act in a network rather than single pathway is likely to be
involved and may lead to the emergence of backup (orBMC Clinical Pharmacology 2005, 5:3 http://www.biomedcentral.com/1472-6904/5/3
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redundant) systems to sustain the disease, or cause unde-
sirable side effects [35-37]. This is a fundamental defect in
the single target reasoning for therapeutic development.
To overcome this problem, a network approach has been
described [20,38,39]. In this network model of pharmaco-
logical actions elements of the network represents various
targets (proteins, RNA-s or DNA sequences), and each link
corresponds to an interaction between proteins of the cell.
Interestingly, application of this model revealed that
multi-target drugs affect their targets only partially, which
corresponds well with the presumed low-affinity interac-
tions of these drugs with several of their targets. Low-affin-
ity, multi-target drugs might have another advantage –
weak links stabilize the systems buffering the changes
after system-perturbations [39,40], thus lower side effects.
Therefore, multi-target drugs and the network approach
might become a useful mean of novel drug discovery.
Many successful drugs are promiscuous. The best known
is aspirin or acetylsalicylic acid known to target any area
where inflammation is present. In recent years, aspirin has
surpassed the area of pain relief to also include activity as
blood thinner, to reduce platelet aggregation in the pre-
vention of cardiovascular disease, prevention of preec-
lampsia (an hypertensive disorders in pregnancy), and
prevention of cancer. Aspirin's antiarthritic effect requires
chronic or long-term therapy for pain and/or inflamma-
tion, e.g., rheumatoid arthritis, juvenile rheumatoid
arthritis, systemic lupus erythematosus, osteoarthritis,
ankylosing spondylitis, psoriatic arthritis, Reiter's syn-
drome, and fibrositis. Aspirin's major mode of activity is
associated with its cyclooxygenase (COX) inhibitory activ-
ity. Cyclooxygenase enzymes are required for the conver-
sion of arachidonic acid to prostaglandins. COX-2
mediates the inflammatory effects, and is induced by a
wide spectrum of growth factors and proinflammatory
cytokines. It is over-expressed in numerous pre-malignant
and malignant lesions, including colorectal and prostate
cancer. Recent papers suggest aspirin and salicylate at ther-
apeutic concentrations inhibit COX-2 protein expression
through interference with binding of CCAAT/enhancer
binding protein beta (C/EBPbeta) to its cognate site on
COX-2 promoter/enhancer. COX-2, is not normally pro-
duced in most tissues but is induced by a wide spectrum
of growth factors and pro-inflammatory cytokines such as
IL-1 and TNF-α , observed in such cell types as synovio-
cytes, endothelial cells, chondrocytes, osteoblasts, and
monocytes/macrophages. Expression of genes, such as
inducible nitric oxide synthase and interleukin-4, may be
inhibited by aspirin and salicylate by a C/EBP-dependent
mechanism Aspirin at supra-pharmacological concentra-
tions inhibits NF-kappaB-mediated gene transcription
and protects tissue from injury. Other pathways yielding
other effects are likely but as yet, uncovered [41-46].
Summary
As discussed, although the basic mechanistic activity of a
drug in a given cell may be relatively simple, the resultan-
tactivity it produces in the human body can be highly
complex. An activity can involve the balance and interplay
of multiple signaling networks and result in unintended
consequences. The pathogenesis of a disease is usually
multi-factorial involving numerous risk factors and defec-
tive proteins or proteins out of balance with each other.
There may be one major or most easily definable defective
target (or pathway)externalized or typifiedfor a given dis-
ease, but collateral proteins which can act in a network
rather than single pathway are likely to be involved and
may lead to the emergence of backup (or redundant) sys-
tems to sustain the disease, or cause undesirable side
effects [35-37]. This is a fundamental defect in the single
target reasoning for therapeutic development.
Consequently, it is conceivable that a perfect drug is not
one that has selectivity for one protein, nor one molecular
mechanism. Such super-selectivity gives a drug maximal
efficacy and minimal adverse effects or toxicity only if the
target of drug is the only one involved in the pathogenesis
of a disease or the target is presented only in the targeted
tissues. This, situation apparently occurs only rarely. Per-
haps, therefore, an ideal drug may be one whose efficacy
is based not on the inhibition of a single target, but rather
on the rebalancing of the several proteins, or events, that
contribute to the etiology, pathogeneses, and progression
of diseases, i.e., in effect a promiscuous drug
Based on the above discussion, one may infer that for con-
trol of some diseases, an "ideal" drug could very well be
one that can hit more than one target, and stimulate/
inhibit more than one molecular activity but do so at a
concentration sufficiently low not to induce undesirable
side effects. When a disease is based on an imbalance of
several proteins or is genetically, physiologically, and ulti-
mately pharmacologically heterogeneous, the logic for
promiscuity in drugs is intuitive. However, it remains to
be seen if drug promiscuity will be superior to targeted
drugs when a disease may be homogeneous. The ability to
detect true homogeneity is the crux of this dilemma.
Nevertheless, when considering all the ramifications of a
rare, ideal case of a single agent affecting a single molecu-
lar-driver, andeven then, having concomitant serious side
effects, one wonders if a broad based and very expensive
screening process used to search for truly selective drugs is
a beguiling, but distracting and perhaps a deluding, appli-
cation of large amounts of research money
Briefly, a promiscuous drug may be advantageous
because:BMC Clinical Pharmacology 2005, 5:3 http://www.biomedcentral.com/1472-6904/5/3
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• Different diseases may have related etiology or similar
pathological alteration.
• Multiple factors contribute to the pathogenesis of a par-
ticular disease.
• Redundancy widely exists in biologically critical path-
ways
• Being promiscuous is not necessarily more toxic.
• Promiscuous drugs do not necessarily completely shut
down or excessively activate a pathway or network
Such drugs are the result of the emerging use of Network
Biology. Network Biology is based on the understanding
of how cellular molecules and their interactions deter-
mine the function of complex cellular machinery, both by
themselves in isolation, as well as with other nearby cells.
Various types of molecular interaction webs (including
protein-protein interaction, metabolic, signaling and
transcription-regulatory networks) emerge from the sum
of these interactions that together are principal determi-
nants of the system-scale behavior of the cell [47].
Further, new technology is being developed related to
screening for the discovery of promiscuous drugs. An
example is the new cell-based high-throughput technol-
ogy for screening chemical libraries against several poten-
tial cancer target genes in parallel. This multiplex gene
expression (MGE) analysis provides direct and quantita-
tive measurement of multiple endogenous mRNAs using
a multiplexed detection system coupled to reverse tran-
scription-PCR [48].
Several brief examples of promiscuous drugs currently
under development include:
1). SU11248 (Pfizer)
SU11248 is a small protein receptor tyrosine kinase inhib-
itor that interferes with several cellular signaling path-
ways. It has with direct anti-tumor as well as
antiangiogenic activity via its multi-targeting process; the
vascular endothelial growth factor (VEGF), platelet-
derived growth factor (PDGF), KIT, and FLT3 receptor
tyrosine kinases.
2). Bay 43-9006 (Bayer)
BAY 43-9006 inhibits a variety of kinase receptors, includ-
ing VEGF and PDGF. It is the first agent to target both the
RAF/MEK/ERK signaling pathway to inhibit cell prolifera-
tion and the VEGFR-2/PDGFR-β  signaling cascade to
inhibit tumor angiogenesis.
3). NTI-2001 (Natrogen Therapeutics)
NTI-2001 regulates two very different avenues associated
with disease pathogeneses. It modulates several cytokines,
e.g., TNF-α  only moderately and so should not do so to
the degree of being a cancer causative, but its modulation
is effective for restoring the cytokine balance, key for the
treatment of inflammatory based diseases. In addition to
regulating such cytokines as Il-1β , Il-6, and Il-10 it can
inhibit Cdks involved in cellular transformation and cel-
lular proliferation. The restoration of cytokine balance
and Cdks inhibition, are both important factors not only
in cancer but in the pathogenesis of other inflammatory
diseases.
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